Blastoschizomyces Capitatus Infection in Acute Leukemia Patients

Pérez-Sánchez, Isabel; Anguita, Javier; Martín‐Rabadán, Pablo; Muñóz, Patricia; Serrano, David; Escudero, Antonio; Pintado, Tomás Ramón

doi:10.3109/10428190009053556

Cited by 31 publications

(28 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, our results confirm the findings of the 3 previous reports that included 12 patients with this infection [1,6,7]. Table 2 shows the results of these 3 previous reports, compared with those of our current study.…”

Section: Discussionsupporting

confidence: 96%

“…Among the emerging yeast pathogens, Blastoschizomyces capitatus is a rarely described yeast that produces severe systemic infection in such patients. Until now, most reports of infection caused by B. capitatus have described only a single case, with only 3 previous studies describing 12 cases [1,6,7]. Here, we report the results of a retrospective study performed in 7 tertiary-care hospitals in Spain that reported у1 case of B. capitatus infection from 1992 through 2002.…”

Section: Twenty-six Cases Ofmentioning

confidence: 72%

See 1 more Smart Citation

Blastoschizomyces capitatusInfection in Patients with Leukemia: Report of 26 Cases

Salavert²,

et al. 2004

View full text Add to dashboard Cite

Twenty-six cases of Blastoschizomyces capitatus infection were diagnosed in 25 patients at 7 tertiary care hematology units in Spain over a 10-year period. Most patients (92%) had acute leukemia and developed infection during a period of severe and prolonged neutropenia. Two patients had esophagitis, and the rest had invasive infection. Fungemia (20 cases) was a common finding, with frequent visceral dissemination. The 30-day mortality associated with this infection was 52%, compared with 57% among patients with systemic infection. In a univariate analysis, the following 3 variables had a positive impact on 30-day survival: removal of the central venous catheter within 5 days after the onset of infection (P=.02), a good performance status (P=.003), and receipt of systemic prophylactic or empirical antifungal therapy before infection onset (P=.006). Outcome for neutropenic patients with B. capitatus infection is still poor. Rapid removal of the central venous catheter and novel antifungal therapies are recommended for treatment of this rare infection.

show abstract

Section: Discussionsupporting

confidence: 96%

Section: Twenty-six Cases Ofmentioning

confidence: 72%

Blastoschizomyces capitatusInfection in Patients with Leukemia: Report of 26 Cases

Salavert²,

et al. 2004

View full text Add to dashboard Cite

show abstract

“…As for the newer antifungal drugs, it is currently impossible to make any predictions of their clinical efficacy. The literature contains reports of only a few cases in which voriconazole or caspofungin was used as initial or salvage antifungal therapy (43,77,101).…”

Section: Discussionmentioning

confidence: 99%

Invasive Infections Caused byTrichosporonSpecies andGeotrichum capitatumin Patients with Hematological Malignancies: a Retrospective Multicenter Study from Italy and Review of the Literature

Girmenia¹,

Pagano

Martino³

et al. 2005

J Clin Microbiol

362

391

View full text Add to dashboard Cite

Trichosporonosis is an uncommon but frequently fatal mycosis in immunocompromised patients 8 and 91.7%, respectively). Well over half of these were suffering from acute leukemia (68 and 84% of patients with Trichosporon sp. and G. capitatum infections, respectively). Crude mortality rates were 77% for Trichosporon spp. and 55.7% for G. capitatum. The optimal therapy for trichosporonosis has yet to be identified; however, in vitro experiences are providing encouraging evidence of the potential role of the new triazoles, in particular, voriconazole.

show abstract

“…Central venous catheter removal (if present) also seems to be an important aspect of treatment (9). Adjuvant therapies advocated by some include hematopoietic growth factors (10), gamma interferon (4), and granulocyte transfusions (8,11).…”

mentioning

confidence: 99%

Case of Fatal Blastoschizomyces capitatus Infection Occurring in a Patient Receiving Empiric Micafungin Therapy

Chittick¹,

Palavecino

Delashmitt³

et al. 2009

Antimicrob Agents Chemother

View full text Add to dashboard Cite

We report the first case, to our knowledge, of Blastoschizomyces capitatus infection occurring in a patient receiving empirical echinocandin therapy for neutropenic fevers. Clinicians should consider B. capitatus infection in those neutropenic patients who remain febrile despite echinocandin therapy or who develop yeast bloodstream infections while receiving an echinocandin.The febrile neutropenic patient has been and continues to be a major therapeutic challenge (5). As our armamentarium of effective prophylactic and empirical treatment options has expanded, the pathogens causing infections have evolved in response to those changes. Using antimicrobial agents with good activity against particular organisms has led to an increasing prevalence of infections with organisms not typically covered by these agents. As an example of this phenomenon, we report the first known case of Blastoschizomyces capitatus infection occurring in a host receiving empirical therapy with an echinocandin.A 65-year-old Caucasian male was admitted to our institution with complaints of fatigue and shortness of breath. A complete blood count at admission revealed pancytopenia, with circulating blasts. The results of a bone marrow biopsy confirmed a diagnosis of acute myelogenous leukemia. A peripherally inserted central venous catheter (PICC) was placed in the patient, and he was treated with cytarabine and daunorubicin. After initial prophylaxis with moxifloxacin, fluconazole, and acyclovir, he became neutropenic and febrile on hospital day 8, at which time he was started on vancomycin and cefepime treatment. A coagulase-negative staphylococcus PICC-associated bloodstream infection was diagnosed, and he responded well to treatment with retention of the PICC. On hospital day 20, he again developed fevers, and fluconazole was changed to micafungin (100 mg daily). The blood cultures were negative, and the patient defervesced while on the same antimicrobial regimen. On hospital day 34, he was begun on total parenteral nutrition due to inadequate oral intake and again developed fevers. His cefepime was changed to meropenem, but his fevers persisted. Over the next 3 days, he manifested worsening renal, hepatic, and pulmonary dysfunction. Multiple blood cultures obtained on hospital days 34, 35, 36, and 37 ultimately all grew Blastoschizomyces capitatus. His PICC was removed on hospital day 35; a culture of the catheter tip was negative. On hospital day 37, the patient's micafungin was changed to amphotericin B lipid complex and intravenous voriconazole on the basis of the first set of cultures yielding positive results, but he died later that day after a cardiopulmonary arrest.

show abstract

Blastoschizomyces Capitatus Infection in Acute Leukemia Patients

Cited by 31 publications

References 10 publications

Blastoschizomyces capitatusInfection in Patients with Leukemia: Report of 26 Cases

Blastoschizomyces capitatusInfection in Patients with Leukemia: Report of 26 Cases

Invasive Infections Caused byTrichosporonSpecies andGeotrichum capitatumin Patients with Hematological Malignancies: a Retrospective Multicenter Study from Italy and Review of the Literature

Case of Fatal Blastoschizomyces capitatus Infection Occurring in a Patient Receiving Empiric Micafungin Therapy

Contact Info

Product

Resources

About